[Adriamycin, cyclophosphamide, and 5-fluorouracil in the treatment of metastasizing breast cancer (author's transl)]
- PMID: 132786
- DOI: 10.1007/BF00284001
[Adriamycin, cyclophosphamide, and 5-fluorouracil in the treatment of metastasizing breast cancer (author's transl)]
Abstract
In a prospective study eleven patients with metastasizing breast cancer were treated with 5-fluorouracil, adriamycin, and cyclophosphamide )FAC). Complete remission occurred in three patients, with two of them still in remission four and thirteen months later. Partial remission (50% decrease in tumour size for more than four weeks) was achieved in five cases, with three of them still in remission. Time for remission induction was one to three months. The mean duration of complete remissions is not yet reached after thirteen months- that of partial remissions was 6.5 months. Two patients showed stable disease for four and more than eleven months, respectively. Only in one case progressive disease was noticed. Mean survival time from the start of therapy was 7.5 months for all patients. For complete and partial responders mean survival is not yet reached after eighteen months. With one exception therapy was given on an outpatient basis. Experimental and clinical data on therapeutic synergism of adriamycin, cyclophosphamide, and 5-fluorouracil show no advantage of the three-drug combination over the combination of adriamycin and cylophosphamide alone.
Similar articles
-
[Encouraging results with cytostatic therapy in metastasizing breast cancer (author's transl)].Wien Klin Wochenschr. 1981 Mar 20;93(6):205-7. Wien Klin Wochenschr. 1981. PMID: 7281697 German.
-
Chemoimmunotherapy of advanced breast cancer: prolongation of remission and survival with BCG.Br Med J. 1976 Nov 20;2(6046):1222-5. doi: 10.1136/bmj.2.6046.1222. Br Med J. 1976. PMID: 791447 Free PMC article. Clinical Trial.
-
Treatment of metastatic breast cancer with adriamycin-cyclophosphamide induction followed by alternating combination therapy.Cancer Treat Rep. 1977 Dec;61(9):1685-9. Cancer Treat Rep. 1977. PMID: 340033 Clinical Trial.
-
Antitumor effect of combination of cyclophosphamide, adriamycin and platinum (CAP) versus cyclophosphamide, adriamycin and 5-fluorouracil (CAF) in metastatic breast cancer.Neoplasma. 1991;38(6):603-7. Neoplasma. 1991. PMID: 1766485 Clinical Trial.
-
[Adriamycin-combination chemotherapy with or without immune stimulation by corynebacterium parvum in metastasizing carcinoma of the breast (author's transl)].Dtsch Med Wochenschr. 1979 Dec 7;104(49):1739-43. doi: 10.1055/s-0028-1129182. Dtsch Med Wochenschr. 1979. PMID: 510206 Clinical Trial. German.